Ginkgo Bioworks Announces Date of Third Quarter 2022 Results Presentation

Ginkgo Bioworks Announces Date of Third Quarter 2022 Results Presentation

Presentation and Q&A session scheduled for post-market on Monday, November 14, 2022

- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2022 on Monday, November 14, 2022 beginning at 4:30 p.m. ET .

The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

To ask a question ahead of the presentation, please submit them to @Ginkgo on Twitter (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com .

About Ginkgo Bioworks

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit https://www.ginkgobioworks.com/ .

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:

investors@ginkgobioworks.com

MEDIA CONTACT:

press@ginkgobioworks.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-date-of-third-quarter-2022-results-presentation-301670154.html

SOURCE Ginkgo Bioworks

News Provided by PR Newswire via QuoteMedia

DNA
The Conversation (0)
CHARBONE Unveils its 2026-2030 Strategic Plan: A Transformation Towards an Integrated High-Value Industrial Gas Group

CHARBONE Unveils its 2026-2030 Strategic Plan: A Transformation Towards an Integrated High-Value Industrial Gas Group

Charbone CORPORATION (TSXV: CH,OTC:CHHYF; OTCQB: CHHYF; FSE: K47) ("Charbone" or the "Company"), a North American producer and distributor specializing in clean Ultra High Purity ("UHP") hydrogen and strategic industrial gases, today announced the rollout of its comprehensive 2026-2030 strategic... Keep Reading...
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period

QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical... Keep Reading...
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe

QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a... Keep Reading...
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News